Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bearish
Hansoh Pharmaceutical Group
Watchlist
Hansoh Pharma (翰森制药) IPO: A Leading Generic Player with Regulatory Overhang (Part 1)
Equity Capital Markets
1.2k Views
20 Dec 2018 02:28
Hansoh Pharma, a leading generic pharmaceutical manufacturer, filed an application to list on the Hong Kong Stock Exchange. In this insight, we...
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 9-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Equity Bottom-Up
Japan
Philippines
Event-Driven
Asia ECM
Unpaywalled Insights
South Korea
India
Singapore REITs
Sell / Short Ideas
Trending Insights
More »
[Japan Buybacks] - Japan Bank Metrics, Cross-Holdings and Banks Part 1
NTT DC REIT IPO: Global Index Inclusions Later This Year + A Kicker
Samsung Electronics: Share Buyback of 3.9 Trillion Won
SICC A/H Listing - Past Growth Has Been Volatile
Breaking Down the Moving Parts in Samsung’s Third-Leg Buyback Play
Top Unpaywalled Insights
More »
China Housing - A Mid-Year Check
Rising OPEC+ Supply & Weak Demand To Drag Crude Price Lower
🧠🎙️ The New Barbarians: AI Agent Edition
Barbarians with Bandwidth: Why Christina Qi Left the Hedge Fund World to Reinvent Data
Curator's Cut: CC Vs DD, Singapore’s IPO Momentum and Pair Trade Ideas Galore
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Hansoh Pharma (翰森制药) IPO: Competitive Landscape of HS-10296, the 3rd Gen EGFR TKI for Lung Cancer
21 May 2019
Hansoh Pharma (翰森制药) IPO: New Numbers, Pre-IPO Dividend and Boyu Investment (Part 3)
30 Apr 2019
Hansoh Pharma (翰森制药) IPO: Takeaways from Recent 4+7 City Centralized Tender Results
03 Jan 2019
Hansoh Pharma (翰森制药) IPO: A Leading Generic Player with Regulatory Overhang (Part 1)
20 Dec 2018
Wuxi Apptec (药明康德) IPO: What You Need to Know Before the Trading Debut
13 Dec 2018
Wuxi Apptec (药明康德) IPO: Pricing Update Before Book Close
06 Dec 2018
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.7
x